The pharmacokinetics of oxypurinol in people with gout

British Journal of Clinical Pharmacology

Volumn 74, Issue 3, 2012, Pages 477-489

  Stocker, Sophie L ^a,b,c   Mclachlan, Andrew J ^a,d   Savic, Radojka M ^c   Kirkpatrick, Carl M ^e   Graham, Garry G ^b,f   Williams, Kenneth M ^b,f   Day, Richard O ^b,f  

^a UNIVERSITY OF SYDNEY   (Australia)

^b ST VINCENT S HOSPITAL   (Australia)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Department of Microbiology and Infectious Diseases   (Australia)

^e MONASH UNIVERSITY   (Australia)

^f UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Allopurinol; Gout; Oxypurinol; Pharmacogenetics; Pharmacokinetics; Urate

Indexed keywords

DIURETIC AGENT; FUROSEMIDE; OXIPURINOL; PROBENECID; THIAZIDE DIURETIC AGENT;

ADULT; AGED; ARTICLE; COMPARTMENT MODEL; DISEASE SEVERITY; DRUG ABSORPTION; DRUG BLOOD LEVEL; DRUG CLEARANCE; FEMALE; GOUT; HUMAN; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; OBSERVATIONAL STUDY; PREDICTION; PRIORITY JOURNAL; QUANTITATIVE ANALYSIS; URIC ACID BLOOD LEVEL;

ADULT; AGED; AGED, 80 AND OVER; DIURETICS; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GOUT; GOUT SUPPRESSANTS; HUMANS; MALE; MIDDLE AGED; MODELS, BIOLOGICAL; NONLINEAR DYNAMICS; OXYPURINOL; PROBENECID; RENAL INSUFFICIENCY; SEVERITY OF ILLNESS INDEX;

EID: 84864809757     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04207.x     Document Type: Article

References (49)

1. Annemans L, Spaepen E, Gaskin M, Bonnemaire M, Malier V, Gilbert T, Nuki G. Gout in the UK and Germany: prevalence, comorbidities and management in general practice 2000-2005. Ann Rheum Dis 2008; 67: 960-6.
2. Riedel AA, Nelson M, Wallace K, Joseph-Ridge N, Cleary M, Fam AG. Prevalence of comorbid conditions and prescription medication use among patients with gout and hyperuricemia in a managed care setting. J Clin Rheumatol 2004; 10: 308-14.
3. Bellamy N, Brooks PM, Emmerson BT, Gilbert JR, Campbell J, McCredie M. A survey of current prescribing practices of anti-inflammatory and urate-lowering drugs in gouty arthritis in New South Wales and Queensland. Med J Aust 1989; 151: 531-2.
4. Terkeltaub RA. Clinical practice. Gout. N Engl J Med 2003; 349: 1647-55.
5. Walter-Sack I, de Vries JX, Kutschker C, Ittensohn A, Voss A. Disposition and uric acid lowering effect of oxipurinol: comparison of different oxipurinol formulations and allopurinol in healthy individuals. Eur J Clin Pharmacol 1995; 49: 215-20.
6. Day RO, Graham GG, Hicks M, McLachlan AJ, Stocker SL, Williams KM. Clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. Clin Pharmacokinet 2007; 46: 623-44.
7. Walter-Sack I, de Vries JX, Kreiner C, Ittensohn A, Stenzhorn G, Voss A, Weber E. Bioequivalence of allopurinol preparations: to be assessed by the parent drug or the active metabolite? Clin Investig 1993; 71: 240-6.
8. Turnheim K, Krivanek P, Oberbauer R. Pharmacokinetics and pharmacodynamics of allopurinol in elderly and young subjects. Br J Clin Pharmacol 1999; 48: 501-9.
9. Metzner JE, Buchberger D, Laeuter J, Pech R. Untersuchungen zur Bioaequivalenz einer neuen Allopurinol-tablettenformulierung im Verglueich zu einer Referenzformulierung. Arzneim-Forsch/Drug Res 1997; 47: 1236-41.
10. Elion GB, Yü TS-F, Gutman AB, Hitchings GH. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 1968; 45: 69-77.
11. Iwanaga T, Kobayashi D, Hirayama M, Maeda T, Tamai I. Involvement of uric acid transporter in increased renal clearance of the xanthine oxidase inhibitor oxypurinol induced by a uricosuric agent, benzbromarone. Drug Metab Dispos 2005; 33: 1791-5.
12. Kobayashi Y, Ohshiro N, Tsuchiya A, Kohyama N, Ohbayashi M, Yamamoto T. Renal transport of organic compounds mediated by mouse organic anion transporter 3 (mOat3): further substrate specificity of mOat3. Drug Metab Dispos 2004; 32: 479-83.
13. Emmerson B, Gordon R, Cross M, Thomson D. Plasma oxipurinol concentrations during allopurinol therapy. Br J Rheumatol 1987; 26: 445-9.
14. Peterson GM, Boyle RR, Francis HW, Oliver NW, Paterson J, von Witt RJ, Taylor GR. Dosage prescribing and plasma oxipurinol levels in patients receiving allopurinol therapy. Eur J Clin Pharmacol 1990; 39: 419-21.
15. Graham S, Day R, Wong H, McLachlan A, Bergendal L, Miners J, Birkett D. Pharmacodynamics of oxypurinol after administration of allopurinol to healthy subjects. Br J Clin Pharmacol 1996; 41: 299-304.
16. Hande KR, Noone RM, Stone WJ. Severe allopurinol toxicity. Description and guidelines for prevention in patients with renal insufficiency. Am J Med 1984; 76: 47-56.
17. Stamp LK, Barclay ML, O'Donnell JL, Zhang M, Drake J, Frampton C, Chapman PT. Relationship between serum urate and plasma oxypurinol in the management of gout: determination of minimum plasma oxypurinol concentration to achieve a target serum urate level. Clin Pharmacol Ther 2011; 63: 412-21.
18. Stamp LK, O'Donnell JL, Zhang M, James J, Frampton C, Barclay ML, Chapman PT. Using allopurinol above the dose based on creatinine clearance is effective and safe in patients with chronic gout, including those with renal impairment. Arthritis Rheum 2011; 63: 412-21.
19. Panomvana D, Sripradit S, Angthararak S. Higher therapeutic plasma oxypurinol concentrations might be required for gouty patients with chronic kidney disease. J Clin Rheumatol 2008; 14: 6-11.
20. Dalbeth N, Kumar S, Stamp L, Gow P. Dose adjustment of allopurinol according to creatinine clearance does not provide adequate control of hyperuricemia in patients with gout. J Rheumatol 2006; 33: 1646-50.
21. Stocker SL, Williams KM, McLachlan AJ, Graham GG, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in healthy subjects. Clin Pharmacokinet 2008; 47: 111-8.
22. Janmahasatian S, Duffull SB, Ash S, Ward LC, Byrne NM, Green B. Quantification of lean bodyweight. Clin Pharmacokinet 2005; 44: 1051-65.
23. Cockcroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31-41.
24. Horne R, Weinman J. Patients' beliefs about prescribed medicines and their role in adherence to treatment in chronic physical illness. J Psychosom Res 1999; 47: 555-67.
25. Ette EI, Williams PJ, Kim YH, Lane JR, Liu MJ, Capparelli EV. Model appropriateness and population pharmacokinetic modeling. J Clin Pharmacol 2003; 43: 610-23.
26. van Kesteren C, Benders MJ, Groenendaal F, van Bel F, Ververs FF, Rademaker CM. Population pharmacokinetics of allopurinol in full-term neonates with perinatal asphyxia. Ther Drug Monit 2006; 28: 339-44.
27. Stocker SL, Graham GG, McLachlan AJ, Williams KM, Day RO. Pharmacokinetic and pharmacodynamic interaction between allopurinol and probenecid in patients with gout. J Rheumatol 2011; 38: 904-10.
28. Tumer N, Scarpace PJ, Lowenthal DT. Geriatric pharmacology: basic and clinical considerations. Annu Rev Pharmacol Toxicol 1992; 32: 271-302.
29. Cusack B, Kelly J, O'Malley K, Noel J, Lavan J, Horgan J. Digoxin in the elderly: pharmacokinetic consequences of old age. Clin Pharmacol Ther 1979; 25: 772-6.
30. Elion GB, Yu TF, Gutman AB, Hitchings GH. Renal clearance of oxipurinol, the chief metabolite of allopurinol. Am J Med 1968; 45: 69-77.
31. Saji M. A study of serum oxipurinol concentration and renal function in patients administered allopurinol. Nippon Jinzo Gakkai Shi 1996; 38: 640-50.
32. Berlinger WG, Park GD, Spector R. The effect of dietary protein on the clearance of allopurinol and oxypurinol. N Engl J Med 1985; 313: 771-6.
33. Janmahasatian S, Duffull SB, Chagnac A, Kirkpatrick CM, Green B. Lean body mass normalizes the effect of obesity on renal function. Br J Clin Pharmacol 2008; 65: 964-5.
34. Yamamoto T, Moriwaki Y, Takahashi S, Tsutsumi Z, Toshikazu H. Effect of furosemide on renal excretion of oxypurinol and purine bases. Metabolism 2001; 50: 241-5.
35. Laragh JH, Cannon PJ, Stason WB, Heinemann HO. Physiologic and clinical observations on furosemide and ethacrynic acid. Ann N Y Acad Sci 1966; 139: 453-65.
36. Choi HK, Atkinson K, Karlson EW, Curhan G. Obesity, weight change, hypertension, diuretic use, and risk of gout in men: the health professionals follow-up study. Arch Intern Med 2005; 165: 742-8.
37. Hasannejad H, Takeda M, Taki K, Shin HJ, Babu E, Jutabha P, Khamdang S, Aleboyeh M, Onozato ML, Tojo A, Enomoto A, Anzai N, Narikawa S, Huang XL, Niwa T, Endou H. Interactions of human organic anion transporters with diuretics. J Pharmacol Exp Ther 2004; 308: 1021-9.
38. Enomoto A, Kimura H, Chairoungdua A, Shigeta Y, Jutabha P, Cha SH, Hosoyamada M, Takeda M, Sekine T, Igarashi T, Matsuo H, Kikuchi Y, Oda T, Ichida K, Hosoya T, Shimokata K, Niwa T, Kanai Y, Endou H. Molecular identification of a renal urate anion exchanger that regulates blood urate levels. Nature 2002; 417: 447-52.
39. Urano W, Taniguchi A, Anzai N, Inoue E, Kanai Y, Yamanaka M, Endou H, Kamatani N, Yamanaka H. Sodium-dependent phosphate cotransporter type 1 sequence polymorphisms in male patients with gout. Ann Rheum Dis 2010; 69: 1232-4.
40. Yang Q, Kottgen A, Dehghan A, Smith AV, Glazer NL, Chen MH, Chasman DI, Aspelund T, Eiriksdottir G, Harris TB, Launer L, Nalls M, Hernandez D, Arking DE, Boerwinkle E, Grove ML, Li M, Linda Kao WH, Chonchol M, Haritunians T, Li G, Lumley T, Psaty BM, Shlipak M, Hwang SJ, Larson MG, O'Donnell CJ, Upadhyay A, van Duijn CM, Hofman A, Rivadeneira F, Stricker B, Uitterlinden AG, Pare G, Parker AN, Ridker PM, Siscovick DS, Gudnason V, Witteman JC, Fox CS, Coresh J. Multiple genetic loci influence serum urate levels and their relationship with gout and cardiovascular disease risk factors. Circ Cardiovasc Genet 2010; 3: 523-30.
41. Hollis-Moffatt JE, Gow PJ, Harrison AA, Highton J, Jones PB, Stamp LK, Dalbeth N, Merriman TR. The SLC2A9 non-synonymous Arg265His variant and gout; evidence for a population-specific effect on severity. Arthritis Res Ther 2011; 13: R85.
42. Phipps-Green AJ, Hollis-Moffatt JE, Dalbeth N, Merriman ME, Topless R, Gow PJ, Harrison AA, Highton J, Jones PB, Stamp LK, Merriman TR. A strong role for the ABCG2 gene in susceptibility to gout in New Zealand Pacific Island and Caucasian, but not Maori, case and control sample sets. Hum Mol Genet 2010; 19: 4813-9.
43. Iharada M, Miyaji T, Fujimoto T, Hiasa M, Anzai N, Omote H, Moriyama Y. Type 1 sodium-dependent phosphate transporter (SLC17A1 Protein) is a Cl(-)-dependent urate exporter. J Biol Chem 2010; 285: 26107-13.
44. Anzai N, Ichida K, Jutabha P, Kimura T, Babu E, Jin CJ, Srivastava S, Kitamura K, Hisatome I, Endou H, Sakurai H. Plasma urate level is directly regulated by a voltage-driven urate efflux transporter URATv1 (SLC2A9) in humans. J Biol Chem 2008; 283: 26834-8.
45. Kolz M, Johnson T, Sanna S, Teumer A, Vitart V, Perola M, Mangino M, Albrecht E, Wallace C, Farrall M, Johansson A, Nyholt DR, Aulchenko Y, Beckmann JS, Bergmann S, Bochud M, Brown M, Campbell H, Connell J, Dominiczak A, Homuth G, Lamina C, McCarthy MI, Meitinger T, Mooser V, Munroe P, Nauck M, Peden J, Prokisch H, Salo P, Salomaa V, Samani NJ, Schlessinger D, Uda M, Volker U, Waeber G, Waterworth D, Wang-Sattler R, Wright AF, Adamski J, Whitfield JB, Gyllensten U, Wilson JF, Rudan I, Pramstaller P, Watkins H, Doering A, Wichmann HE, Spector TD, Peltonen L, Volzke H, Nagaraja R, Vollenweider P, Caulfield M, Illig T, Gieger C. Meta-analysis of 28, 141 individuals identifies common variants within five new loci that influence uric acid concentrations. PLoS Genet 2009; 5: e1000504.
46. Vitart V, Rudan I, Hayward C, Gray NK, Floyd J, Palmer CN, Knott SA, Kolcic I, Polasek O, Graessler J, Wilson JF, Marinaki A, Riches PL, Shu X, Janicijevic B, Smolej-Narancic N, Gorgoni B, Morgan J, Campbell S, Biloglav Z, Barac-Lauc L, Pericic M, Klaric IM, Zgaga L, Skaric-Juric T, Wild SH, Richardson WA, Hohenstein P, Kimber CH, Tenesa A, Donnelly LA, Fairbanks LD, Aringer M, McKeigue PM, Ralston SH, Morris AD, Rudan P, Hastie ND, Campbell H, Wright AF. SLC2A9 is a newly identified urate transporter influencing serum urate concentration, urate excretion and gout. Nat Genet 2008; 40: 437-42.
47. Briesacher BA, Andrade SE, Fouayzi H, Chan KA. Comparison of drug adherence rates among patients with seven different medical conditions. Pharmacotherapy 2008; 28: 437-43.
48. Harrold LR, Andrade SE, Briesacher BA, Raebel MA, Fouayzi H, Yood RA, Ockene IS. Adherence with urate-lowering therapies for the treatment of gout. Arthritis Res Ther 2009; 11: R46.
49. Phatak HM, Thomas J, 3rd. Relationships between beliefs about medications and nonadherence to prescribed chronic medications. Ann Pharmacother 2006; 40: 1737-42.